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Autoantibodies directed against cellular antigens are frequently found in the 
connective tissue diseases (1,2). In myositis, an inflammatory condition of muscle, 
the antigens are often cytoplasmic rather than nuclear components (3,  4).  We 
recently identified two such antigens as aminoacyl-tRNA synthetases; anti-Jo-1 
antibody,  found in  25-30%  of myositis sera  (2,  4),  reacts  with histidyl-tRNA 
synthetase  (3),  and  PL-7  antibody,  found in  5%  of cases,  is  directed  against 
threonyl-tRNA synthetase (5).  Both antibodies  immunoprecipitate ribonucleo- 
protein complexes containing the enzyme and its transfer RNA; they recognize 
the protein free of RNA, but do not recognize the RNA alone. Here we describe 
a  third myositis-related autoantibody, PL-12, that inhibits alanyl-tRNA synthe- 
tase.  Both the enzyme and tRNA  Area are  immunoprecipitated, but in this case, 
distinct sets of antibodies react with each component independently. Further- 
more, antibody against the synthetase fails to recognize the enzyme bound to its 
cognate tRNA. We discuss the possibility that one antibody may be an antiidi- 
otype to the other. 
Materials and Methods 
Sera.  This study is based on sera shown by ourselves and others to immunoprecipitate 
tRNA from extracts of3~P-labeled HeLa cells. Serum samples (patients 3-6) were provided 
by Drs. J. Keene, J. A. Hardin, J. A. Steitz, and R. Reddy. Serum Ha (6) and serum LL 
(7), a sample of the tRNA-1  specificity (8), are included among the sera reported here. 
IgG was prepared  by chromatography through DEAE-Sephadex A50  (Pharmacia Fine 
Chemicals, Piscataway, N  J), as described previously (5). 
Immunoprecipitation of RNA and Protein.  HeLa cells labeled with [sSS]methionine  or 
[32p]phosphate  (NEX 054; New England Nuclear, Boston, MA) were harvested, washed, 
and lysed in buffer A (5, 9). Immunoprecipitations were conducted as described previously 
(5), using IgGSORB (Tufts-New England Medical  Center, Boston, MA)  to precipitate 
immune complexes made by incubating cell extract with patients' IgG. Proteins dissociated 
from the precipitate were resolved by electrophoresis in  15% SDS-polyacrylamide gels 
and detected by fluorography (10,  11). Immunoprecipitated RNA was resolved in 7 M 
urea/10% polyacrylamide gels.  Immunoblotting was performed according to the proce- 
dure of Towbin et al. (12). 
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TABLE  I 
Clinical Features of Six Patients with PL-12 Antibody 
Patient  Sex  Age (yr)  Clinical notes 
1  Female  60 
2  Female  60 
3  Female  48 
4  Male  60 
5  Female  35 
6  Female  -- 
8-yr history of myositis, Raynaud's phenomenon, sicca syn- 
drome, sclerodactyly,  arthritis, and pulmonary fibrosis 
2-yr history of myositis, Raynaud's phenomenon, sicca syn- 
drome, arthritis, and pulmonary fibrosis; preceded by mastec- 
tomy and chemotherapy for carcinoma 6 yr earlier 
Fatal pulmonary fibrosis preceded by a 16-too history of myosi- 
tis, Raynaud's phenomenon, and swollen fingers 
8-yr history of myositis, Raynaud's phenomenon, and pulmo- 
nary fibrosis 
5-yr history of adult Still's disease and widespread tenosynovitis 
(7, 8) 
SLE (6) 
Aminoacylation oftRNA.  Standard reactions (25 #1) contained 90 ~g calf liver tRNA, a 
HeLa cell extract  containing  charging  enzymes,  one  SH-labeled amino acid (or [3~S]- 
methionine or [sSS]cysteine), IgG as specified, and other components as described previ- 
ously  (3,  5).  Aiiquots  (5  #1)  were removed for determination  of cold TCA-insoluble 
radioactivity.  In some experiments, the charging enzyme extract was preabsorbed with 
PL-12 IgG bound to protein  A-Sepharose (5) to deplete it of PL-12 antigens  before 
incubation.  To  examine  the  amino  acid acceptance  of PL-12  RNA,  PL-12  IgG  was 
incubated with a fourfold excess (by weight) of HeLa cell cytoplasmic RNA, and absorbed 
to protein A-Sepharose. RNA was isolated from the washed immunoprecipitate by phenol 
and chloroform extraction followed by ethanol precipitation. 
Removal of Anti-tRNA Antibody.  Calf liver tRNA (Boehringer-Mannheim  Diagnostics, 
Houston, TX) was bound to cyanogen bromide-activated Sepharose 4  B (1.25  #tool 
ligand  per  milliliter  of gel)  using  the procedure  recommended  by the  manufacturer 
(Pharmacia  Fine Chemicals). Any unreacted sites were blocked with Tris base. ~25% of 
the tRNA was bound. Control adsorbants were prepared in the same way by omitting 
tRNA or substituting  heat-denatured calf thymus DNA (Sigma Chemical Co., St. Louis, 
MO). Antibody was eluted from the adsorbant with 20 mM triethylamine,  pH 12.4 
Results 
Antibody Frequency and Clinical Association.  Six examples of the autoantibody 
specificity under  study were recognized by the identical patterns of tRNA and 
protein bands they gave on immunoprecipitation.  Subsequently, a precipitin line 
was  detected  by  counterimmunoelectrophoresis  (13),  and  the  specificity  was 
named  PL-12.  Four  of the  six  examples  were  derived  from  patients  with  a 
syndrome of myositis, pulmonary fibrosis, and Raynaud's phenomenon; the fifth 
and  sixth  patients  has  episodes of arthritis  and  fever (Table I).  In  our British 
series of patients with myositis, the frequency of the antibody was ~3% (data not 
shown). 
PL-12  IgG  Recognizes  Two Antigens.  All  six  PL-12  isolates  precipitated  an 
[35S]methionine-labeled protein of 1 1  0  kD (Fig.  1 A).  In two cases, the identity 
of the  immunoprecipitated  polypeptides  was  confirmed  by  comparing  their 
partial proteolysis products; identical peptide patterns were obtained (Fig.  1 C). 
The protein remained precipitable after digestion of the cell extract with ribon- 
uclease (Fig.  1 A) under conditions that destroyed the precipitability of both U 1- FIGURE  1.  Polypeptides recognized by PL-12 antibodies. (A) Protein precipitated from [ssS]- 
methionine-labeled HeLa cell extract by normal IgG (lane I), PL-12 IgG (lanes 2-7), and PL- 
7 IgG (lanes 8 and 9).  The extract was pretreated with RNase at 0.5 mg/ml for 5 min at 37°C 
for lanes 4, 6, and 8. PL-12 IgG from patients 4, 3, 2, and  I were used in lanes 2, 3, 4 and 5, 
and  6  and  7.  (B)  Immunoblot (from a  10%  gel) reacted with serum  1.  Lane 2,  HeLa cell 
extract;  lanes 3-5,  three  PL-12  IgG isolates; lane  1, sSS-labeled  PL-12 protein, not reacted 
with serum 1 or ~2Sl-protein A. (C) Partial proteolysis of PL-12 protein precipitated by sera 4 
(left) and 5  (right),  digested with 0, 5,  50, and 500 ng (lanes  1-4) S.  aureus  V8 protease (4). 
Positions of molecular weight markers are shown. 
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FIGURE 2.  RNA recognized by PL-12 antibody.  RNA was precipitated  from s~p-labeled 
HeLa cell extracts by PL-7, Jo-1, PL-12, and control IgG (lanes 1-4). Lanes 5 and 6, PL-12 
precipitates from standard and deproteinized extracts, respectively; lane 7, extract RNA as 
marker. 
RNA  by  anti-RNP  (3)  and  of tRNA  Ala  by  PL-12  antibody  (not  shown).  The 
protein  was  also  detected  by  immunoblotting  after  transfer  to  nitrocellulose 
paper and probing with one of the PL-12 isolates (Fig.  1 B). These results show 
that the  110 kD protein is recognized directly by the antibody. 
Immunoprecipitates from 32P-labeled extracts revealed several bands of RNA 
in the tRNA size range (Fig.  2). The exact banding pattern varied slightly from 
experiment to  experiment,  but  was  simplified when  freshly prepared  extracts 
were  used,  suggesting  that  some  of the  complexity  might  be  due  to  partial BUNN ET  AL.  1285 
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FIGURE 3.  Inhibition oftRNA charging by PL-12 antibodies. (A) Effect  of increasing  amount 
of PL-12 IgG on aminoacylation  with [SH]alanine. Incubation was for 10 min. (B-D) Kinetics 
of charging of [SH]alanine, [3H]histidine,  and [3Hlthreonine, respectively,  in the presence of 
two isolates  of PL-12 IgG (F'l, l) Jo-1 IgG (A), PL-7 IgG (V), or no IgG (O). 
TABLE II 
Aminoacylation in PL-12-depleted Extracts 
[SH]Amino acids charged (cpm) 
Amino acid 
Control  PL- 12-depleted 
Alanine  1,550  70 
Lysine  3,360  3,440 
Tryptophan  3,090  3,110 
A HeLa cell extract, pretreated  with PL-12 IgG bound to protein A- 
Sepharose to deplete PL-12 antigens, was assayed for aminoacyl-tRNA 
synthetase activities with added calf liver tRNA. All 20 amino acids were 
tested; only alanyl-tRNA  synthetase was removed. 
degradation of the  RNA.  The  PL-12  tRNAs were  electrophoretically distinct 
from tRNA  His and tRNA  TM  precipitated by anti-Jo-1  and PL-7 antibodies. The 
PL-12  tRNA  remained  precipitable  when  extracts  were  deproteinized  with 
pronase and phenol (Fig. 2) before reaction with antibody. The six PL-12 IgGs 
gave the same banding pattern, and all were able to precipitate naked tRNA, in 
contrast to the otherwise comparable Jo-1 and PL-7 antibodies studied previously 
(3, 5).  To exclude the possibility that RNA precipitation was due to incomplete 
removal of protein,  sSS-labeled cell extracts were deproteinized by phenol ex- 
traction; no protein was detected in the immunoprecipitate (not shown). We also 
considered the possibility that the IgG samples might contain free protein antigen 
that  could  bind  to  RNA  and  account  for  the  precipitation  of naked  RNA; 
however, no antigen was detected in the IgG samples by immunoblotting (Fig. 
1 B). We conclude that PL-12 antibodies react with both the 1 10 kD protein and 
with tRNA species. 
Identity of the Protein Antigen.  By analogy with theJo-1 and PL-7 specificities, 
which both react with charging enzymes (3,  5), we examined the ability of PL- 
12 IgG to inhibit the aminoacylation of tRNA. As shown in Fig. 3, the addition 
of increasing amounts of PL-12 IgG led to a progressive decrease in the rate of 
tRNA charging with alanine. No other amino acids were affected, as exemplified 
here with histidine and threonine. All four of the PL-12 isolates tested specifically 
inhibited alanine charging. To exclude the possibility that the block was due to 
the binding of antibody to tRNA  Al~ or to the addition of a nonspecific inhibitor, 
we carried out the depletion experiment shown in Table II. When the charging 1286  AUTOANTIBODIES AGAINST A TRANSFER RNA AND  ITS  SYNTHETASE 
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FIGURE 4.  Charging of RNA immunoprecipitated by PL-12 antibody. (A and B) Titration 
of PL-12 and calf liver tRNA, respectively, into aminoacylation  reactions containing [3H]- 
alanine (O) or [3H]threonine (O). (C and D) Kinetics of aminoacylation  with [SH]alanine  and 
[3H]valine, respectively,  comparing reactions with PL-12 RNA (0), calf liver tRNA (I), and 
no tRNA (O). All 20 amino acids were tested in this way; only alanine was charged. 
extract was treated with PL-12 IgG immobilized on protein A-Sepharose before 
addition of tRNA and the other components of the reaction mixture, subsequent 
aminoacylation with alanine was again greatly reduced, whereas charging with 
the other 19 amino acids was unaffected. The protein antigen is therefore alanyl- 
tRNA synthetase. 
Identity of the RNA Antigen.  The fingerprint of the PL-12 RNA (not shown) 
was complex and consistent with the presence  of more  than one  species.  We 
therefore turned to aminoacylation reactions with the RNA immunoprecipitated 
by PL-12 IgG to make an identification. As shown in Fig. 4A, PL-12 tRNA could 
be charged efficiently with alanine but not with threonine, whereas unfraction- 
ated calf liver tRNA accepted both amino acids (Fig. 4B). On a weight basis, PL- 
12  tRNA  was  charged  with alanine  ~13-fold  more  efficiently than  calf liver 
tRNA, and its amino acid acceptor activity exceeded 0.5 mol alanine per mole 
tRNA. Using each amino acid in turn, we compared the acceptor activity of PL- 
12 RNA and calf liver tRNA in kinetic experiments like those of Fig. 4, C and 
D.  With  the  exception  of alanine,  no  incorporation  above  background  was 
detected  with  any  of the  other  amino  acids.  These  results  show  that  PL-12 
antibodies recognize tRNA  A~a. Direct sequence analysis and hybridization to a BUNN  ET  AL.  1287 
FmURE 5.  Properties of anti-alanyl-tRNA synthetase antibody. (A) Immunoprecipitation 
from ssS-labeled extract with 0.2, 0.9, and  1.8 t~g untreated PL-12 IgG (lanes 1-3); 1.8 #g 
PL-12 IgG preadsorbed with Sepharose-tRNA (lane 4); or no lgG (lane 5). (B) Immunopre- 
cipitation of RNA from deproteinized s2P-labeled extract by untreated PL-12 IgG (lane 4), 
and by PL-I 2 IgG preabsorbed with Sepharose (lane I), Sepharose-DNA (lane 2), Sepharose- 
tRNA (lane 3). (C) As in B, except that the ~2P-labeled extract was not deproteinized before 
immunoprecipitation. 
cloned Bombyx mori  tRNA  Ala gene  (14)  confirms that at  least two isoaccepting 
forms of this RNA are present in the immunoprecipitate (C. C. Bunn and M. B. 
Mathews, manuscript in preparation). 
Distinct Antibodies  against tRNA and Protein.  The data described so far show 
that  PL-12  antibodies are  directed at alanyl-tRNA synthetase and its cognate, 
tRNA  Ala. These two reactivities coexist in all six isolates of this specificity available 
to us, implying either that separate antiprotein and anti-tRNA antibodies occur 
in all cases, or that a  single antibody specificity crossreacts with both antigenic 
moieties. 
To distinguish between these two possibilities, PL-! 2  IgG was incubated with 
tRNA immobilized on an inert matrix. Antibodies precleared in this way were 
unable to immunoprecipitate tRNA (Fig. 5B), whereas precipitation of the  110 
kD protein antigen was unimpaired (Fig. 5A). As expected, antibody eluted from 
the adsorbant efficiently precipitated tRNA  ala (data not shown). No loss of anti- 
tRNA activity was occasioned by pretreatment of the antibody with Sepharose 
that had been incubated with calf thymus DNA or without nucleic acid (Fig. 5B). 
To our surprise precleared PL-12 IgG not only failed to recognize naked tRNA 
but also failed to coprecipitate tRNA with the enzyme from whole cell extracts 
(Fig.  5C).  To  be  sure  that excess  unlabeled tRNA  had not  leached from the 1288  AUTOANTIBODIES  AGAINST  A  TRANSFER  RNA  AND  ITS  SYNTHETASE 
tRNA-Sepharose matrix and competed with labeled RNA in this experiment, we 
conducted control immunoprecipitations in the presence of precleared PL-12 
IgG or of a deproteinized extract therefrom. The ability of antibody to precipi- 
tate [S2P]tRNA was not significantly impaired by prior mixing with preabsorbed 
PL-12  IgG  itself,  or  with  material  prepared  from  it  by  phenol/chloroform 
extraction and  alcohol  precipitation.  Similarly,  immunoprecipitation by  PL-7 
antibody was unaffected. These experiments discount the release of substantial 
amounts of tRNA from the immunoadsorbant. We conclude that, at least in the 
two cases studied,  the  PL-12  specificity contains two  separate populations  of 
antibodies: one set recognizes alanyl-tRNA synthetase, possibly only in its tRNA- 
unbound form, while the second set is directed against tRNA  AI~. 
Discussion 
Six human sera of the PL-12 specificity immunoprecipitated a protein of 110 
kD, as well as tRNA from HeLa cell extracts. In all cases, the protein and tRNA 
were recognized independently. The antibodies inhibited aminoacylation with 
alanine, identifying the protein antigen as alanyl-tRNA synthetase. The immu- 
noprecipitated tRNA efficiently accepted alanine but none of the other amino 
acids, identifying the RNA antigen as tRNA  Ala. After preabsorption with tRNA 
bound  to  Sepharose,  PL-12  IgG  still  recognized the protein  antigen,  but  no 
longer  precipitated  tRNA  from  deproteinized  RNA,  showing  that  the  two 
components are recognized by separate antibodies. The preabsorbed IgG also 
failed to coprecipitate tRNA with the protein antigen from whole cell extracts, 
a finding which may indicate that the enzyme is recognized only in a tRNA-free 
state. 
Antisynthetase antibodies of the Jo-1  and  PL-7  specificities are not accom- 
panied by detectable levels of antibody against tRNA, although they coprecipitate 
tRNA with the enzyme (3,  5).  The  PL-12  system differs in both  respects;  its 
antisynthetase antibodies are unable to precipitate the antigen in tRNA-bound 
form, while other antibodies in  the same sera react directly with  tRNA.  The 
absence of coprecipitating tRNA could be attributed to instability of the complex 
between alanyl-tRNA synthetase and tRNA  Ala, but it is not clear why this complex 
should  be  less  stable  than  those  containing  tRNA  His  or  tRNA  vhr  and  their 
charging enzymes. The instability argument is weakened further by the existence 
of experimental rabbit antibodies that resemble PL-7 autoantibodies in reacting 
with threonyl-tRNA synthetase but differ in that they fail to coprecipitate tRNA 
(5). It is possible, therefore, that anti-alanyl-tRNA synthetase antibody binds the 
protein in such a way as to preclude binding of tRNA. 
These observations are consistent with the idea that one PL-12 antibody is an 
antiidiotype to the other (15-18) and with the general hypothesis that autoanti- 
bodies are antiidiotypes of antiviral antibodies (19).  We have argued (20) that 
the available  evidence does  not  sustain  this  idea  so  far  as  ribonucleoprotein 
antigens are concerned, but support could be adduced from the complementary 
activities of PL-12 antibodies reported here. Antiidiotype antibodies, directed at 
the  antigen-combining  site  of antibodies  against  tRNA  AI~, might  themselves 
mimic tRNA  AI~ and bind to the charging enzyme in its place. Perhaps it is more 
likely, in view of the other autoantibodies against aminoacyl-tRNA synthetases BUNN  ET  AL.  1289 
(3,  5),  that  PL-12  antiprotein  antibody  incited an  antiidiotype response  that 
recognizes tRNA  Ala. This  would explain both  the coexistence of two types of 
antibody in PL-12 sera and the absence of coprecipitating tRNA. In an effort to 
test this idea, we have attempted to block antibody binding to the synthetase by 
competition with an excess of tRNA. No inhibition of synthetase immunoprecip- 
itation was observed (unpublished data), but the relative affinities of antibody 
and tRNA for the synthetase are unknown. In progress are more direct tests, 
including the determination of the synthetase and  antibody binding  sites  on 
tRNA  Ala. 
The concurrence of antibodies to alanyl-tRNA synthetase and tRNA  Ala in the 
same serum is also reminiscent of other cases where autoimmune sera contain 
antibodies  to  more  than  one component of a  macromolecular complex.  For 
example, lupus sera may contain antibodies reactive with several components of 
the nucleosome (DNA, poly(ADP-ribose), histones) (21-23), ribosome (proteins 
and  high  molecular  weight  RNA)  (2),  and  small  nuclear  ribonucleoproteins 
(snRNP) particles (several proteins with "Sm" or "RNP" reactivity) (24). Antibod- 
ies to Ro and La also often occur together, and the Ro and La protein antigens 
are related in that they bind overlapping sets of RNAs, and may be associated at 
least transiently (25).  An interpretation of these observations is that antibodies 
are generated against the whole particle or complex, perhaps because a change 
in one component leads to an antihapten-like response to associated macromol- 
ecules. Changes in the nucleic acid moiety may be of particular importance (2, 
3).  Simultaneous  autoimmunity  to  several  components  of a  complex  argues 
against the hypothesis (26) that autoantibodies are initially raised against foreign 
immunogens and crossreact merely by chance with host components. 
Autoimmunity to aminoacyl-tRNA synthetases is closely associated with myo- 
sitis (3, 5), particularly with a syndrome of myositis, fibrosing alveolitis, Raynaud's 
phenomenon, and  sicca syndrome (27).  Four  of the patients  with  antibodies 
against alanyl-tRNA synthetase and tRNA  Ala were suffering from this condition. 
In the other two cases, our clinical data are incomplete. Despite their effects in 
vitro, little evidence suggests that immunoglobulins are able to penetrate living 
cells, making it seem unlikely that these antibodies have a  major pathogenetic 
effect in vivo. Rather, we believe they may be a clue to etiology, possibly pointing 
to a viral origin of the disease (3). 
Summary 
The sera of six patients with autoimmune disease, predominantly myositis with 
pulmonary fibrosis, contain antibodies of the PL-12 specificity. These autoanti- 
bodies react with both protein and RNA components of human cells. The protein 
has a  subunit molecular mass of 1 I0  kD, and the RNA comprises a  group of 
bands in the tRNA size class.  Aminoacylation experiments identify the antigens 
as alanyl-tRNA synthetase and its corresponding tRNAs,  tRNA  Ala. Anti-tRNA 
antibody can be absorbed out without depleting antisynthetase activity, showing 
that  the  antigens  are  recognized independently by  separable  antibodies  that 
coexist in these sera. The concurrence of separate antibodies to the two compo- 
nents  suggests  that  the  autoimmune  response  may  be  mounted  against  the 
charging enzyme-tRNA complex. However, the antisynthetase antibody fails to 1290  AUTOANTIBODIES AGAINST A  TRANSFER  RNA  AND  ITS SYNTHETASE 
coprecipitate tRNA with the enzyme, suggesting that the antibody reacts with its 
target only when it is not complexed with tRNA. 
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